NCT06926387

Bioequivalence Study betweenYHP2407 and YHR2502 in Healthy Subjects

An Open-label, Randomized, Single-dose, Oral Administration, 2-sequence, 2- Period, Crossover Study to Evaluate Bioequivalence Between YHP2407 and YHR2502 in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 43 (actual)
• Sponsor: Yuhan Corporation · Industry
• Sex: All
• Age: 19 Years – 64 Years
• Healthy volunteers: Accepted

Summary

A randomized, open-label, single-dose, 2-sequence, 2-period, crossover clinical trial to investigate the bioequivalence between YHP2407 and YHR2502 in healthy volunteers

Detailed description

40 healthy subjects will be randomized to one of the 2 groups in the same ratio. Subjects in group 1 will be administered "comparator" and "YHP2407" by crossover design on period 1, 2. Subjects in group 2 will be administered "YHP2407" and "comparator" by crossover design on period 1, 2.

Conditions

• Healthy Volunteer

Interventions

Type	Name	Description
DRUG	YHP2407	Test drug: YHP2407, Comparator: YHR2502
DRUG	YHR2502	Test drug: YHP2407, Comparator: YHR2502

Timeline

• Start date: 2025-04-17
• Primary completion: 2025-04-19
• Completion: 2025-04-29
• First posted: 2025-04-13
• Last updated: 2025-05-13

Locations

1 site across 1 country: South Korea